Psoriasis Biologics Face Off in Drug Survival Study
January 14, 2026
-
2 min
7 Key Takeaways
-
1
Ustekinumab has the highest drug survival for bionaive patients.
-
2
5-year discontinuation rate for ustekinumab is 37%.
-
3
Bimekizumab, guselkumab, and risankizumab show better rates for bioexperienced patients.
-
4
Analysis based on DERMBIO registry data covering 4,438 patients.
-
5
23% of bionaive patients have comorbid psoriatic arthritis.
-
6
Drug survival varies significantly based on previous treatment experience.
-
7
Study led by Christopher Willy Schwarz, MD, PhD.
A recent cohort study analyzed biologic therapy for psoriasis among patients in Denmark, evaluating drug survival rates between bionaive and bioexperienced patients. Ustekinumab exhibited the highest drug survival among bionaive patients, with a 5-year discontinuation rate of 37%, while bimekizumab, guselkumab, and risankizumab had better 2-year rates among bioexperienced patients. Data from the DERMBIO registry from 2007 to 2025 included 4,438 patients, emphasizing the importance of biologic selection in clinical practice.
Listen Tab content
